Tessa Romero
Stock Analyst at JP Morgan
(3.85)
# 1,114
Out of 4,479 analysts
39
Total ratings
43.75%
Success rate
12.71%
Average return
Main Sectors:
Top Industries:
13 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Maintains: Overweight | $77 → $65 | $54.84 | +18.53% | 3 | Jun 24, 2024 | |
| AGIO Agios Pharmaceuticals | Reinstates: Neutral | $46 | $42.05 | +9.39% | 4 | Jun 13, 2024 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Overweight | $35 → $32 | $8.01 | +299.50% | 2 | Jun 4, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Overweight | $29 → $25 | $15.84 | +57.83% | 4 | Mar 25, 2024 | |
| NMRA Neumora Therapeutics | Maintains: Overweight | $20 → $22 | $9.80 | +124.49% | 3 | Mar 18, 2024 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Overweight | $32 → $56 | $34.17 | +63.89% | 4 | Feb 23, 2024 | |
| LXEO Lexeo Therapeutics | Initiates: Overweight | $20 | $14.02 | +42.65% | 1 | Nov 28, 2023 | |
| YMAB Y-mAbs Therapeutics | Maintains: Underweight | $8 → $7 | $11.37 | -38.43% | 5 | Aug 22, 2023 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $20 → $22 | $34.65 | -36.51% | 2 | Aug 9, 2023 | |
| EWTX Edgewise Therapeutics | Maintains: Overweight | $24 → $25 | $18.38 | +36.02% | 6 | Jun 30, 2023 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $54 → $55 | $36.56 | +50.44% | 2 | Apr 25, 2023 | |
| MCRB Seres Therapeutics | Initiates: Neutral | $7 | $0.70 | +898.57% | 1 | Apr 21, 2023 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $38 → $20 | $7.63 | +162.12% | 2 | Nov 18, 2022 |
Cytokinetics
Jun 24, 2024
Maintains: Overweight
Price Target: $77 → $65
Current: $54.84
Upside: +18.53%
Agios Pharmaceuticals
Jun 13, 2024
Reinstates: Neutral
Price Target: $46
Current: $42.05
Upside: +9.39%
EyePoint Pharmaceuticals
Jun 4, 2024
Maintains: Overweight
Price Target: $35 → $32
Current: $8.01
Upside: +299.50%
ACADIA Pharmaceuticals
Mar 25, 2024
Maintains: Overweight
Price Target: $29 → $25
Current: $15.84
Upside: +57.83%
Neumora Therapeutics
Mar 18, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $9.80
Upside: +124.49%
Biohaven Pharmaceutical Holding Company
Feb 23, 2024
Maintains: Overweight
Price Target: $32 → $56
Current: $34.17
Upside: +63.89%
Lexeo Therapeutics
Nov 28, 2023
Initiates: Overweight
Price Target: $20
Current: $14.02
Upside: +42.65%
Y-mAbs Therapeutics
Aug 22, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $11.37
Upside: -38.43%
Dyne Therapeutics
Aug 9, 2023
Maintains: Overweight
Price Target: $20 → $22
Current: $34.65
Upside: -36.51%
Edgewise Therapeutics
Jun 30, 2023
Maintains: Overweight
Price Target: $24 → $25
Current: $18.38
Upside: +36.02%
Xenon Pharmaceuticals
Apr 25, 2023
Maintains: Overweight
Price Target: $54 → $55
Current: $36.56
Upside: +50.44%
Seres Therapeutics
Apr 21, 2023
Initiates: Neutral
Price Target: $7
Current: $0.70
Upside: +898.57%
Scholar Rock Holding
Nov 18, 2022
Maintains: Overweight
Price Target: $38 → $20
Current: $7.63
Upside: +162.12%